肽治疗市场基于(主要区域、市场参与者、规模和份额)- 预测至 2031 年

  • Report Code : TIPRE00003793
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

肽类药物市场规模预计将从 2023 年的 293.5 亿美元增至 2031 年的 736.3 亿美元。预计 2023-2031 年市场复合年增长率将达到 11.5%。肽类药物的普及率不断提高、生产速度的降低和新技术的采用可能仍是肽类药物市场的主要趋势。

肽治疗市场分析

随着全球慢性病负担的增加,对有针对性和有效治疗方法的需求也在增加。肽疗法以其精确性和特异性被证明是一种满足各种慢性病治疗需求的引人注目的解决方案。强大的研究渠道预示着未来将充满新颖和突破性的肽疗法。向个性化医疗的转变与肽疗法的独特性质相一致。由于肽在治疗罕见疾病方面显示出希望,制药公司专注于为小众患者群体开发治疗解决方案。合成方法的创新带来了更复杂和更专业的肽,扩大了医疗保健专业人员可用的治疗武器库。此外,科学家和市场参与者在研究计划中的共同努力推动了肽疗法市场的创新。此外,合作伙伴关系和联盟创造了协同效应,推动了尖端肽疗法的发展。然而,严格的法规和高昂的药物开发成本预计将抑制市场增长。

肽类治疗市场概况

肽疗法市场正在成为制药行业中一个充满活力且前景光明的新兴领域,为治疗各种疾病和医疗状况提供了独特的方法。由短氨基酸序列组成的肽疗法因其特异性、有效性和在各种治疗领域的潜在应用而备受关注。这个新兴市场处于创新和医学科学的交汇处,有望重塑医疗保健格局。市场包括各种肽,从天然肽到合成类似物,旨在改善治疗效果。这些肽是针对特定受体、酶或细胞机制的多功能药物,使其成为精准医疗的宝贵工具。

定制研究以满足您的需求

我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。

肽治疗市场:

肽类治疗市场
  • Peptide Therapeutics Market
    复合年增长率(2023 - 2031)
    11.5%
  • 2023 年市场规模
    293.5 亿美元
  • 2031年市场规模
    736.3亿美元

市场动态

增长动力
  • 肽疗法投资不断增加
未来的趋势
  • 强调自动肽合成
机会
  • 肽的操作限制

关键人物;主力;重要一员

  • 礼来公司,
  • 安进公司(Amgen Inc.)、
  • 梯瓦制药工业有限公司
  • 龙沙,
  • 赛诺菲,
  • 百时美施贵宝公司,
  • 葛兰素史克公司
  • 阿斯利康,
  • 辉瑞公司,
  • 诺和诺德

区域概况

Peptide Therapeutics Market
  • 北美
  • 欧洲
  • 亚太
  • 南美洲和中美洲
  • 中东和非洲

市场细分

Peptide Therapeutics Market类型
  • 通用的
  • 创新的
Peptide Therapeutics Market给药途径
  • 肠外
  • 口服
  • 粘膜
  • 肺部
  • 其他的
Peptide Therapeutics Market合成技术
  • 固相肽合成
Peptide Therapeutics Market应用
  • 癌症
  • 心血管疾病
  • 代谢紊乱
  • 呼吸系统疾病
  • 疼痛管理
  • 皮肤科
  • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

肽治疗市场驱动因素和机遇

代谢紊乱和传染病患病率上升,利好市场

根据美国国家医学图书馆的一篇文章,传染病仍然是全球疾病和死亡的主要原因,每年导致全球超过 5200 万人死亡。根据 2021 年 12 月发布的 IDF,墨西哥估计有 1400 万成年人患有糖尿病。酰胺 (GLP-1) 等肽可有效治疗糖尿病。2022 年 2 月,新斯科舍省政府报告称,新斯科舍省人已在药物保健计划中注册,该计划将开始改用某些生物药物的生物仿制药,包括一些胰岛素和药物,用于治疗克罗恩病和风湿病。一些代谢性疾病(如器官功能障碍、遗传性疾病和线粒体功能障碍)病例的增加是推动市场增长的因素之一。葡萄糖脑苷脂在巨噬细胞中逐渐储存,主要储存在骨骼、骨髓、脾脏和肝脏中,这是戈谢病 (GD) 的症状,这是一种常染色体隐性溶酶体贮积症。根据《儿科血液学/肿瘤学杂志》 (JPHO) 的数据,2022 年 7 月,全球每 100,000 名活产婴儿中 GD 病例的患病率为 1.5。因此,传染病和代谢性疾病的高患病率推动了对用于治疗这些疾病的肽疗法的需求,从而促进了市场增长。

肽类药物的强大产品线和应用——肽类治疗市场增长的机会

最常见的肽适应症是肿瘤学、内分泌学和代谢疾病。其他受到关注的肽目标领域包括胃肠病学、心血管疾病、皮肤病学、骨病和性功能障碍。由于其高免疫原性,肽疫苗也具有成为传统疫苗替代品的巨大潜力,因为它们是完全合成的并且不会引起不良副作用。为了克服它们的局限性,已经引入了肽的各种修饰。此外,与肽应用相关的正在进行的研究预计将对管道产生积极影响,从而为市场增长提供有利可图的机会。一些肽药物管道如下:

公司

治疗领域

发展阶段

3B Pharmaceuticals(德国)

FAP-2286

肿瘤学-FAP 表达肿瘤

I期临床试验

3B 401

神经内分泌肿瘤

临床前试验

Allysta Pharmaceuticals(美国)

ALY688

眼科-干眼症

II期临床试验

ALY688SR

肝脏疾病和肥胖症

I期临床试验

资料来源:Issar Pharma、Willing Wellness

肽治疗市场报告细分分析

有助于得出肽治疗市场分析的关键部分是组件、应用和最终用户。

  • 根据类型,肽治疗市场分为仿制药和创新药。创新药在 2023 年占据了最大的市场份额,而仿制药预计在预测期内将实现最高的复合年增长率。
  • 根据给药途径,市场分为肠外给药、口服给药、粘膜给药、肺部给药和其他给药。肠外给药在 2023 年占据了最大的市场份额,而口服给药预计在 2023-2031 年期间的复合年增长率最高。
  • 根据合成技术,肽治疗市场分为固相肽合成 (SPPS)、液相肽合成 (LPPS)、混合技术。固相肽合成部分在 2023 年占据了最大的市场份额。然而,混合技术部分预计在预测期内将实现最高的复合年增长率。
  • 从应用方面来看,市场细分为癌症、心血管疾病、代谢疾病、呼吸系统疾病、疼痛和皮肤病学。癌症领域在 2023 年占据了最大的市场份额。然而,代谢疾病领域预计在 2023-2031 年期间的复合年增长率最高。

肽类治疗药物市场份额按地区分析

肽治疗市场报告的地理范围主要分为五个区域:北美、亚太、欧洲、中东和非洲、南美/南美和中美。

北美主导了肽治疗市场。北美市场的增长归功于著名的学术机构、最先进的实验室以及科学与工业之间的合作,这些合作形成了充满活力的研发生态系统,促进了具有治疗潜力的新型肽的发现和开发。在北美,生物技术部门在开发肽治疗方面发挥着重要作用。领先的生物技术公司的存在和支持​​性的监管环境促进了将研究成果转化为临床可行的肽类治疗方法,使北美成为全球肽治疗领域的领导者。北美慢性病的流行凸显了对先进治疗方案的需求。凭借其有针对性的作用机制,肽治疗被证明是治疗糖尿病、心血管疾病 (CVD) 和各种癌症等疾病的有希望的候选药物。预计亚太地区未来几年将以最高的复合年增长率增长。

肽治疗市场报告范围

报告属性细节
2023 年的市场规模293.5亿美元
2031 年市场规模736.3亿美元
全球复合年增长率(2023 - 2031)11.5%
历史数据2021-2022
预测期2023-2031
涵盖的领域按类型
  • 通用的
  • 创新的
按给药途径
  • 肠外
  • 口服
  • 粘膜
  • 肺部
  • 其他的
通过合成技术
  • 固相肽合成
按应用
  • 癌症
  • 心血管疾病
  • 代谢紊乱
  • 呼吸系统疾病
  • 疼痛管理
  • 皮肤科
覆盖地区和国家北美
  • 我们
  • 加拿大
  • 墨西哥
欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
亚太
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
南美洲和中美洲
  • 巴西
  • 阿根廷
  • 南美洲和中美洲其他地区
中东和非洲
  • 南非
  • 沙特阿拉伯
  • 阿联酋
  • 中东和非洲其他地区
市场领导者和主要公司简介
  • 礼来公司,
  • 安进公司(Amgen Inc.)、
  • 梯瓦制药工业有限公司
  • 龙沙,
  • 赛诺菲,
  • 百时美施贵宝公司,
  • 葛兰素史克公司
  • 阿斯利康,
  • 辉瑞公司,
  • 诺和诺德
  • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

肽治疗市场新闻和最新发展

肽治疗市场通过收集一级和二级研究后的定性和定量数据进行评估,其中包括重要的公司出版物、协会数据和数据库。以下是肽治疗市场的发展列表:

  • 诺和诺德宣布,美国食品药品监督管理局 (FDA) 批准了 Wegovy 的一项额外适应症,即在低热量饮食和增加身体活动的情况下,降低患有已知心脏病且肥胖或超重的成年人发生死亡、心脏病发作或中风等重大心血管事件的风险。(Novo Nordisk A/S,新闻稿,2024 年)
  • 小野制药株式会社宣布与 PeptiDream Inc. 达成药物发现合作协议,以发现和开发针对多个靶点的新型大环限制肽药物。根据协议条款,PeptiDream 将利用其专有的肽发现平台系统 (PDPS) 技术,识别和优化针对小野选定的多个目标的大环限制肽药物候选物。(来源:小野制药株式会社,新闻,2023 年)
  • 生命科学行业关键材料供应商 Biosynth 宣布收购英国合成肽生产商 Pepceuticals,该公司拥有多公斤级 GMP 设施和灌装能力,旨在为客户提供从临床试验到商业供应的支持。此次收购使产品生命周期从发现到商业化的所有阶段都能够得到支持。(来源:Biosynth,新闻,2023 年)
  • 创新合同研究组织 IRBM 宣布已与默克公司签署新协议,继续在肽治疗领域开展合作。此次合作将 IRBM 在肽设计和合成方面的一流科学专业知识与默克公司卓越的药物开发能力相结合,重点是为有需要的患者提供创新疗法。(来源:IRBM SpA;新闻稿;2023 年)
  • 北海道大学的研究人员开发出了一种设计和大量开发肽类抗生素的新方法,这对于控制抗生素耐药性至关重要。(北海道大学,新闻稿,2023 年)

肽治疗市场报告覆盖范围和交付成果

“肽治疗市场规模和预测(2021-2031)”报告对市场进行了详细分析,涵盖以下领域:

  • 范围内所有主要细分市场的全球、区域和国家层面的市场规模和预测
  • 市场动态,如驱动因素、限制因素和关键机遇
  • 未来主要趋势
  • 详细的 PEST/波特五力分析和 SWOT 分析
  • 全球和区域市场分析涵盖关键市场趋势、主要参与者、法规和最新市场发展
  • 行业格局和竞争分析,涵盖市场集中度、热点图分析、知名参与者和最新发展
  • 详细的公司简介
  • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
  • PEST and SWOT Analysis
  • Market Size Value / Volume - Global, Regional, Country
  • Industry and Competitive Landscape
  • Excel Dataset
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Trends and growth analysis reports related to Life Sciences : READ MORE..   
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Buy Now  

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.